These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 16306032)

  • 41. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1.
    Murphy RL; Sommadossi JP; Lamson M; Hall DB; Myers M; Dusek A
    J Infect Dis; 1999 May; 179(5):1116-23. PubMed ID: 10191212
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Stavudine plus didanosine and nevirapine in antiretroviral-naive HIV-infected adults: preliminary safety and efficacy results. VIRGO Study Team.
    Raffi F; Reliquet V; Francois C; Garre M; Hascoet C; Allavena C; Arvieux C; Breux JP; Perre P; Rozenbaum W; Auger S
    Antivir Ther; 1998; 3 Suppl 4():57-60. PubMed ID: 10723512
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics of nevirapine in HIV-infected infants weighing 3 kg to less than 6 kg taking paediatric fixed dose combination tablets.
    Fillekes Q; Mulenga V; Kabamba D; Kankasa C; Thomason MJ; Cook A; Ferrier A; Chintu C; Walker AS; Gibb DM; Burger DM
    AIDS; 2012 Sep; 26(14):1795-800. PubMed ID: 22739394
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients.
    Bickel M; Bodtländer A; Knecht GK; Stephan C; von Hentig N; Kurowski M; Gute P; Klauke S; Lutz T
    J Antimicrob Chemother; 2009 Dec; 64(6):1260-4. PubMed ID: 19776037
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Do we still need lead-in dosing of nevirapine in HIV-infected patients who are receiving rifampicin-containing antituberculous therapy?
    Chang SY; Lin SW; Hung CC
    Clin Infect Dis; 2009 Nov; 49(9):1452-3; author reply 1453-4. PubMed ID: 19824849
    [No Abstract]   [Full Text] [Related]  

  • 46. Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach.
    Moltó J; Valle M; Miranda C; Cedeño S; Miranda J; Santos JR; Negredo E; Vilaró J; Costa J; Clotet B
    J Antimicrob Chemother; 2008 Oct; 62(4):784-92. PubMed ID: 18593723
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bioavailability of extended-release nevirapine 400 and 300 mg in HIV-1: a multicenter, open-label study.
    Battegay M; Arasteh K; Plettenberg A; Bogner JR; Livrozet JM; Witt MD; Mossdorf E; Yong CL; Zhang W; Macha S; Berger F; Stern J; Robinson P; Quinson AM
    Clin Ther; 2011 Sep; 33(9):1308-20. PubMed ID: 21872931
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand.
    Vanprapar N; Cressey TR; Chokephaibulkit K; Muresan P; Plipat N; Sirisanthana V; Prasitsuebsai W; Hongsiriwan S; Chotpitayasunondh T; Eksaengsri A; Toye M; Smith ME; McIntosh K; Capparelli E; Yogev R;
    Pediatr Infect Dis J; 2010 Oct; 29(10):940-4. PubMed ID: 20453709
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of once and twice daily dosing of didanosine in combination with stavudine for the treatment of HIV-1 infection. AI 454-146 Team.
    Monno L; Cargnel A; Soranzo ML; Chirianni A; Ferraro T; Di Stefano M; Angarano G
    Antivir Ther; 1999; 4(4):195-202. PubMed ID: 10723498
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Influence of nevirapine administration on the pharmacokinetics of dolutegravir in patients infected with HIV-1.
    Dailly E; Allavena C; Grégoire M; Reliquet V; Bouquié R; Billaud E; Hernando H; Bouchez S; Deslandes G; Hall N; Jolliet P; Raffi F
    J Antimicrob Chemother; 2015 Dec; 70(12):3307-10. PubMed ID: 26271944
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals.
    Almond LM; Edirisinghe D; Dalton M; Bonington A; Back DJ; Khoo SH
    Clin Pharmacol Ther; 2005 Aug; 78(2):132-42. PubMed ID: 16084848
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-vir) in advanced HIV infection.
    Getahun A; Tansuphasawadikul S; Desakorn V; Dhitavat J; Pitisuttithum P
    J Med Assoc Thai; 2006 Sep; 89(9):1472-8. PubMed ID: 17100387
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily.
    Arroyo E; Valenzuela B; Portilla J; Climent-Grana E; Pérez-Ruixo JJ; Merino E
    Eur J Clin Pharmacol; 2007 Jul; 63(7):669-75. PubMed ID: 17473920
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets.
    Pollock L; Else L; Poerksen G; Molyneux E; Moons P; Walker S; Fraser W; Back D; Khoo S
    J Antimicrob Chemother; 2009 Dec; 64(6):1251-9. PubMed ID: 19812065
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children.
    Chokephaibulkit K; Cressey TR; Capparelli E; Sirisanthana V; Muresan P; Hongsiriwon S; Ngampiyaskul C; Limwongse C; Wittawatmongkol O; Aurpibul L; Kabat B; Toye M; Smith ME; Eksaengsri A; McIntosh K; Yogev R;
    Antivir Ther; 2011; 16(8):1287-95. PubMed ID: 22155910
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministration.
    Ramachandran G; Hemanthkumar AK; Rajasekaran S; Padmapriyadarsini C; Narendran G; Sukumar B; Sathishnarayan S; Raja K; Kumaraswami V; Swaminathan S
    J Acquir Immune Defic Syndr; 2006 May; 42(1):36-41. PubMed ID: 16639340
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates.
    Cressey TR; Punyawudho B; Le Coeur S; Jourdain G; Saenjum C; Capparelli EV; Jittayanun K; Phanomcheong S; Luvira A; Borkird T; Puangsombat A; Aarons L; Sukrakanchana PO; Urien S; Lallemant M;
    J Acquir Immune Defic Syndr; 2017 Aug; 75(5):554-560. PubMed ID: 28489732
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).
    Podzamczer D; Ferrer E; Consiglio E; Gatell JM; Perez P; Perez JL; Luna E; González A; Pedrol E; Lozano L; Ocaña I; Llibre JM; Casiró A; Aranda M; Barrufet P; Martínez-Lacasa J; Miró JM; Badía X; Casado A; Lupo S; Cahn P; Maños M; Estela J
    Antivir Ther; 2002 Jun; 7(2):81-90. PubMed ID: 12212928
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Limited sampling models to predict the pharmacokinetics of nevirapine, stavudine, and lamivudine in HIV-infected children treated with pediatric fixed-dose combination tablets.
    Burger D; Ewings F; Kabamba D; L'homme R; Mulenga V; Kankasa C; Thomason M; Gibb DM; Chintu C; Walker AS
    Ther Drug Monit; 2010 Jun; 32(3):369-72. PubMed ID: 20386361
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A once-daily HAART regimen containing indinavir + ritonavir plus one or two nucleoside reverse transcriptase inhibitors (PIPO study).
    Burger DM; Aarnoutse RE; Dieleman JP; Gyssens IC; Nouwen J; de Marie S; Koopmans PP; Stek M; van der Ende ME
    Antivir Ther; 2003 Oct; 8(5):455-61. PubMed ID: 14640393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.